Seminars in Oncology
Volume 36, Issue 2 , Pages 181-189 , April 2009

Management of Gestational Trophoblastic Neoplasia

References 

  1. Bagshawe KD. Risks and prognostic factors in trophoblastic neoplasia. Cancer. 1976;38:1373–1385
  2. Goldstein DP, Berkowitz RS. Gestational trophoblastic neoplasms—clinical principles of diagnosis and management. Philadelphia: Saunders; 1982;1
  3. Lurain JR, Singh DK, Schink J. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med. 2006;51:767–772
  4. Martin BH, Kim JM. Changes in gestational trophoblastic tumors over four decades: a Korean experience. J Reprod Med. 1998;43:60–68
  5. Bracken MB. Incidence and aetiology of hydatidiform mole: an epidemiologic review. Br J Obstet Gynaecol. 1987;94:1123–1135
  6. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med. 1994;39:155–162
  7. Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll DG, Goldstein DP. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol. 1985;152:1016–1020
  8. Parazzini F, LaVecchia C, Mangili G, Caminiti C, Negri E, Cecchetti G, et al. Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol. 1988;158:93–99
  9. O'Toole BA, Fradkin R, Warkany J. Vitamin A deficiency and reproduction in rhesus monkeys. J Nutr. 1974;104:1513–1524
  10. Fulop V, Mok SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases; a review. J Reprod Med. 2004;49:415–422
  11. Kajii T, Ohama K. Androgenetic origin of hydatidiform mole. Nature. 1977;268:633–634
  12. Pattillo RA, Sasaki S, Katayama KP, Roesler M, Mattingly RF. Genesis of 46,XY hydatidiform mole. Am J Obstet Gynecol. 1981;141:104–105
  13. Yamashita K, Wake N, Araki T, Ichinoe K, Makoto K. Human lymphocyte antigen expression in hydatidiform mole: androgenesis following fertilization by a haploid sperm. Am J Obstet Gynecol. 1979;135:597–600
  14. Azuma C, Saji F, Tokugawa Y, Kimura T, Nobunaga T, Takemura M, et al. Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of anuclear empty ovum as the cause of complete mole. Gynecol Oncol. 1991;40:29–33
  15. Szulman AE, Surti U. The syndromes of hydatidiform mole: II (Morphologic evolution of the complete and partial mole). Am J Obstet Gynecol. 1978;132:20–27
  16. Castrillon DH, Sun D, Weremowicz S, Fisher RA, Crum CP, Genest DR. Discrimination of complete hydatidiform mole from its mimick by immunohistochemistry of the paternally imprinted gene product p57(KIP2) immunostaining. Am J Surg Pathol. 2001;25:1225–1230
  17. Genest DR, Ruiz RE, Weremowicz S, Berkowitz RS, Goldstein DP, Dorfman DM. Do nontriploid partial hydatidiform moles exist? (A histologic and flow cytometric re-evaluation of nontriploid specimens). J Reprod Med. 2002;47:363–368
  18. Lage JM, Mark SD, Roberts D, Goldstein DP, Bernstein MR, Berkowitz RS. A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol. 1992;79:403–410
  19. Lawler SD, Fisher RA, Dent J. A prospective genetic study of complete and partial hydatidiform moles. Am J Obstet Gynecol. 1991;164:1270–1277
  20. Berkowitz RS, Goldstein DP, Anderson DJ. Recent advances in understanding the immunobiology of gestational trophoblastic disease—a review. Trophoblast Res. 1987;2:123
  21. Ito H, Sekine T, Komuro N, Tanaka T, Yokoyama S, Hosokawa T. Histologic stromal reaction of the host with gestational choriocarcinoma and its relation to clinical stage, classification and prognosis. Amer J Obstet Gynecol. 1981;140:781–786
  22. Berkowitz RS, Hill JA, Kurtz CB, Anderson DJ. Effects of products of activated leukocytes (lymphokines and monokines) on the growth of malignant trophoblast cells in vitro. Am J Obstet Gynecol. 1988;158:199–203
  23. Berkowitz RS, Hornig-Rohan J, Martin-Alosco S, Klein S, Goldstein DP, Bast RC, et al. HLA antigen frequency distribution in patients with gestational choriocarcinoma and their husbands. Placenta Suppl. 1981;3:263–267
  24. Lawler SD, Klouda PT, Bagshawe KD. The HL-A system in trophoblastic neoplasia. Lancet. 1971;2:834–837
  25. Tomoda Y, Fuma M, Saiki N, Ishizuka N, Akaza T. Immunologic studies in patients with trophoblastic neoplasia. Am J Obstet Gynecol. 1976;126:661–667
  26. Morgensen B, Kissmeyer-Nielsen F, Hauge M. Histocompatibility antigens on the HL-A locus in gestational choriocarcinoma. Transplant Proc. 1969;1:76–79
  27. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. p53, p21, Rb, and MdM2 oncoproteins: expression in normal placenta, partial and complete mole and choriocarcinoma. J Reprod Med. 1998;43:119–127
  28. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowtiz RS. c-myc, c-erb B-2, c-fms, and bcl-2 oncoproteins—expression in normal placenta, partial and complete mole and choriocarcinoma. J Reprod Med. 1998;43:101–110
  29. Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med. 2004;49:415–422
  30. Tuncer ZS, Vegh GL, Fulop V, Genest GR, Mok SC, Berkowitz RS. Expression of epidermal growth factor receptor related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol. 2000;77:389–393
  31. Vegh GL, Tuncer ZS, Fulop V, Genest GR, Mok SC, Berkowitz RS. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol Oncol. 1999;75:248–253
  32. Matsuda T, Sasaki M, Kato H, Yamada H, Cohen M, Barrett JC, et al. Human chromosome 7 carries a putative tumor suppressor gene (s) involved in choriocarcinoma. Oncogene. 1997;15:2773–2781
  33. Ahmed MN, Kim K, Haddad B, Berchuck A, Oumsiyeh MB. Comparative genome hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma. Cancer Genet Cytogenet. 2004;116;:10–15
  34. Burke B, Sebire NJ, Moss J, Hodges MD, Seckl MJ, Newlands ES, et al. Evaluation of deletions in 7q11.2 and 8p12-p21 as prognostic indicators of tumor development following molar pregnancy. Gynecol Oncol. 2006;103:642–648
  35. Hodges MD, Rees HC, Seckl MJ, Newlands ES, Fisher RA. Genetic refinement and physical mapping of a biparental complete mole locus on chromosome 19q 13.4. J Med Genet. 2003;40:e95
  36. Berkowitz RS, Goldstein DP. Presentation and management of molar pregnancy. In:  Hancock BW,  Newlands ES,  Berkowitz RS editor. Gestational trophoblastic disease. 127:London: Chapman and Hall; 1997;
  37. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management and long-term follow up of 347 patients. Obstet Gynecol. 1975;45:1–8
  38. Kohorn EI. Molar pregnancy: presentation and diagnosis. Clin Obstet Gynecol. 1984;27:181–191
  39. Soto-Wright V, Bernstein MR, Goldstein DP, Berkowitz R. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol. 1995;86:775–779
  40. Hou JL, Wan XR, Xiang Y, Oi OW, Yang XY. Changes of clinical features in hydatidiform mole: an analysis of 113 cases. J Reprod Med. 2008;53:629–633
  41. Berkowitz RS, Goldstein DP, Bernstein MR. Natural history of partial molar pregnancy. Obstet Gynecol. 1985;66:677–681
  42. Mosher R, Goldstein DP, Berkowitz RS, Bernstein M, Genest DR. Complete hydatidiform mole—comparison oclinicopathologic features, current and past. J Reprod Med. 1998;43:21–27
  43. Keep D, Zaragoza MV, Hasold T, Redline RW. Very early complete hydatidiform mole. Hum Pathol. 1996;27:708–713
  44. Berkowitz RS, Goldstein DP. Management of molar pregnancy and gestational trophoblastic tumors. In:  Knapp RC,  Berkowitz RS editor. Gynecologic oncology. 328:New York: McGraw-Hill; 1993;
  45. Garrett LA, Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. J Reprod Med. 2008;53(7):481–486Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med. In press.
  46. Parazzini F, Mangili G, Belloni C, La Vecchia C, Liati P, Marabini R. The problem of identification of prognostic factors for persistent trophoblastic disease. Gynecol Oncol. 1988;30:57–62
  47. Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole: incidence and outcome. J Reprod Med. 2006;51:764–766
  48. Feltmate CM, Growdon WB, Wolfberg AJ, Goldstein DP, Genest DR, Chinchilla ME, et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51:902–906
  49. Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med. 1996;335:1740–1748
  50. Hancock BW, Tidy JA. Current management of molar pregnancy. J Reprod Med. 2002;47:347–354
  51. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol. 1986;67:690–694
  52. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med. 2001;46:110–116
  53. Wolfberg AJ, Feltmate CM, Goldstein DP, Berkowitz RS, Lieberman E. Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy. Obstet Gynecol. 2004;104:551–554
  54. Wolfberg AJ, Growdon WB, Feltmate CM, Genest DR, Chincilla ME, Berkowitz RS. Low risk of relapse after achieving undetectable hCG levels in women with partial molar pregnancy. Obstet Gynecol. 2006;108:393–396
  55. Stone M, Dent J, Kardana A, Bagshawe KD. Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole. Br J Obstet Gynaecol. 1976;83:913–916
  56. Berkowitz RS, Goldstein DP, Marean AR, Bernstein MR. Oral contraceptives and postmolar trophoblastic disease. Obstet Gynecol. 1981;58:474–477
  57. Curry SL, Schlaerth JB, Kohorn EI, Boyce JB, Gore H, Twiggs LB, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1989;160:805–809
  58. Paradinas FJ, Fisher RA. Pathology and molecular genetics and trophoblastic disease. Current Obstet Gynecol. 1995;5:6
  59. Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, Rustin GJ. Management of brain metastases in patients with high risk gestational trophoblastic tumours (GTT). J Reprod Med. 2002;47:465–471
  60. Bakri YN, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. J Reprod Med. 1994;39:179–184
  61. Cagayan MS, Lu-Lasala LR. Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: a 12 year review at the Philippine General Hospital. J Reprod Med. 2006;51:785–792
  62. Athanassiou A, Begent RH, Newlands ES, Parker D, Rustin GJ, Bagshawe KD. Central nervous system metastases of choriocarcinoma: 23 years' experience at Charing Cross Hospital. Cancer. 1983;52:1728–1735
  63. Bakri YN, Subhi J, Amer M, Ezzat A, Sinner W, Tweijry A, et al. Liver metastases of gestational trophoblastic tumor. Gynecol Oncol. 1993;48:110–113
  64. Berkowitz RS, Birnholz J, Goldstein DP, Bernstein MR. Pelvic ultrasonography and the management of gestational trophoblastic disease. Gynecol Oncol. 1983;15:403–412
  65. Mangili G, Spagnolo D, Valsecchi L, Maggi R. Transvaginal ultrasound in persistent trophoblastic tumor. Am J Obstet Gynecol. 1993;169:1218–1223
  66. Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med. 2006;51:879–887
  67. Berkowitz RS, Osathanondh R, Goldstein DP, Martin PM, Mallampati SR, Datta S. Cerebrospinal fluid human chorionic gonadotropin levels in normal pregnancy and choriocarcinoma. Surg Gynecol Obstet. 1981;153:687–689
  68. Mutch DG, Soper JT, Baker ME, Bandy LC, Cox EB, Clarke-Pearson DL, et al. Role of computed axial tomography of the chest in staging patients with nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1986;68:348–352
  69. Garner EIO, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med. 2004;49:411
  70. Osborne R, Filiaci V, Schink J, Mannel R, Provencher D, Alvarez-Secord A, et al. A randomized phase III trial comparing weekly parenteral methotrexate and pulsed dactinomycin as primary management of low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:S2
  71. Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–181
  72. Rustin GJS, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single–agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996;14:2769–2773
  73. Sekhara PK, Sreedevi NS, Radhadevi VP, Beegam R, Raghavan J, Guhan B. Management of postmolar gestational trophoblastic disease with methotraxate and folinic acid: 15 years experience. J Reprod Med. 2006;51:835–840
  74. Feldman S, Goldstein DP, Berkowitz RS. Low-risk metastatic gestational trophoblastic tumors. Semin Oncol. 1995;22:166–171
  75. Ayhan A, Yapar EG, Deren O, Kisnisci H. Remission rates and significance of prognostic factors in gestational trophoblastic tumors. J Reprod Med. 1992;37:461–465
  76. DuBeshter B, Berkowitz RS, Goldstein DP, Cramer DW, Bernstein MR. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965–1985. Obstet Gynecol. 1987;9:390–395
  77. Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. Five day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994;54:76–79
  78. Newlands ES, Bower M, Holden L, Short D, Seckl MJ, Rustin GJ, et al. Management of resistant gestational trophoblastic tumors. J Reprod Med. 1998;43:111–118
  79. Bagshawe KD. Treatment of high-risk choriocarcinoma. J Reprod Med. 1984;29:813–820
  80. Evans AC, Soper JT, Clarke-Pearson DL, Berchuck A, Rodriquez GC, Hammond CB. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol. 1995;59:226–230
  81. Brace KC. The role of irradiation in the treatment of metastatic trophoblastic disease. Radiology. 1968;91:540
  82. Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, Rustin GJ. Management of brain metastases in patients with high-risk gestational trophoblastic tumor. J Reprod Med. 2002;47:465–471
  83. Alazzam M, Hancock B, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med. 2008;53(7):519–524
  84. Lurain JR, Singh DK, Schink JL. Role of surgery in management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2006;51;:773–776
  85. Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol. 2006;103:479–482
  86. Edwards JL, Makey AR, Bagshawe KD. The role of thoracotomy in the management of pulmonary metastases of gestational choriocarcinoma. Clin Oncol. 1975;1:329–339
  87. Fleming EL, Garrett L, Growdon WB, Callahan M, Nevadunsky N, Ghosh S, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med. 2008;53:493–498
  88. Sink JD, Hammond CB, Young WG. Pulmonary resection in the management of metastases from choriocarcinoma. J Thorac Cardiovasc Surg. 1981;81:830
  89. Wang Y, Song H, Xia Z. Drug resistant pulmonary choriocarcinoma metastasis treated by lobectomy. Chin Med J. 1980;93:758–766
  90. Lehman E, Gershenson DM, Burke TW, Levenback C, Silva EG, Morris M. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol. 1994;12:2737–2742
  91. Tomoda Y, Arii Y, Kaseki S, Asai Y, Gotoh S, Suzuki T, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer. 1980;46:2723–2730
  92. Cole LA. hCG, its free subunits and its metabolites—roles in pregnancy and trophoblastic disease. J Reprod Med. 1998;43:3–10
  93. Cole LA. Detecting and monitoring trophoblastic disease (New perspectives in measuring human chorionic gonadotropin levels for measuring and monitoring trophoblastic disease). J Reprod Med. 1994;39:193–200
  94. Cole LA, Butler S. Detection of hCG in trophoblastic disease—the USA hCG Reference Service experience. J Reprod Med. 2002;47:433–444
  95. Hancock BW. hCG measurement in gestational trophoblastic neoplasia: a critical appraisal. J Reprod Med. 2006;51:859–860
  96. Mitchell H, Bagshawe KD, Newlands ES, Savage P, Seckl MJ. Importance of accurate human chorionic gonadotropin measurement in the treatment of gestational trophoblastic disease and testicular cancer. J Reprod Med. 2006;51:868–870
  97. Cole LA, Kohorn EI. The need for an hCG assay that appropriately detects trophoblastic disease and other hCG-producing tumors. J Reprod Med. 2006;51:793–811
  98. Khanlian SA, Cole LA. Management of gestational trophoblastic disease and other cases with low serum levels of human chorionic gonadotropin. J Reprod Med. 2006;51:812–818
  99. Kohorn EI. What we know about low-level hCG: definition, classification and management. J Reprod Med. 2004;49:433–437
  100. Hwang D, Hancock BW. Management of persistent, unexplained, low-level human chorionic gonadotropin elevation: a report of 5 cases. J Reprod Med. 2004;49:559–562
  101. Goldstein DP, Zanten-Przybysz I, Bernstein MR, Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors; recommendations regarding therapy. J Reprod Med. 1998;43:37–43

PII: S0093-7754(08)00266-2

doi: 10.1053/j.seminoncol.2008.12.009

Seminars in Oncology
Volume 36, Issue 2 , Pages 181-189 , April 2009

Article Tools